CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera closes €9M ($10.3M) Series B funding round to launch multi-center trial in patients with recurrent glioblastoma and develop clinical pipeline

Read more

Our innovative solutions

CarThera’s medical devices allow for the treatment of brain tumors in outpatient procedures as well as for improvement in the bioavailability of chemotherapeutics

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

CarThera closes €9M ($10.3M) Series B funding round to launch multi-center trial in patients with recurrent glioblastoma and develop clinical pipeline

Read more

SonoCloud®

High Intensity Contact Ultrasound interstitial medical device

An implant that increases the intracerebral penetration of oncology drugs (+400%) by transiently opening the blood-brain barrier (BBB) without increasing dose or subsequent toxicity. The minimally invasive and easy to use SonoCloud® device is also applicable to the treatment of neurodegenerative diseases (e.g. Alzheimer’s).

Read more

 

SonoProbe®

High Intensity Contact Ultrasound interstitial medical device

img2

The only medical device capable of performing biopsy, treatment, and resection of brain tumors in a single, image-guided outpatient procedure, even for complex tumor geometries

The SonoProbe can also be used for the treatment of tumors located in other organs such as the liver or lung

Read more

Home Page
  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.